Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database - Archive ouverte HAL Access content directly
Journal Articles BMC Clinical Pharmacology Year : 2011

Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database

(1) , (1, 2) , (1, 2) , (1, 2)
1
2

Abstract

Background
Thiazolidinediones (TZDs), rosiglitazone (RGZ) and pioglitazone (PGZ) are widely used as hypoglycemic drugs in patients with type 2 diabetes mellitus. The aim of our study was to investigate the profile of adverse drug reactions (ADRs) related to TZDs and to investigate potential risk factors of these ADRs.
Methods
Type 2 diabetic patients were identified from the French Database of PharmacoVigilance (FPVD) between 2002 and 2006. We investigated ADR related to TZD, focusing on 4 ADR: edema, heart failure, myocardial infarction and hepatitis corresponding to specific WHO-ART terms.
Results
Among a total of 99,284 adult patients in the FPVD, 2295 reports concerned type 2 diabetic patients (2.3% of the whole database), with 161 (7%) exposed to TZDs. The frequency of edema and cardiac failure was significantly higher with TZDs than in other patients (18% and 7.4% versus 0.8% and 0.1% respectively, p < 0.001) whereas the frequency of hepatitis was similar (5.9% versus 4%, NS). A multiple logistic regression model taking into account potential confounding factors (age, gender, drug exposure and co-morbidities) found that TZD exposure remained associated with heart failure and edema, but not with hepatitis or myocardial infarction.
Conclusions
Thiazolidinediones exposure is associated with an increased risk of edema and heart failure in patients with type 2 diabetes even when recommendations for use are respected. In contrast, the risk of hepatic reactions and myocardial infarction with this class of drugs seems to be similar to other hypoglycemic agents.
Fichier principal
Vignette du fichier
1472-6904-11-5.pdf (170.72 Ko) Télécharger le fichier
Vignette du fichier
1472-6904-11-5.xml (64.83 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Format : Other

Dates and versions

inserm-00668416 , version 1 (09-02-2012)

Identifiers

Cite

Stephanie Berthet, Pascale Olivier, Jean-Louis Montastruc, Maryse Lapeyre-Mestre. Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database. BMC Clinical Pharmacology, 2011, 11 (1), pp.5. ⟨10.1186/1472-6904-11-5⟩. ⟨inserm-00668416⟩
117 View
249 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More